Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Observational Prolonged Trial in Myotonic Dystrophy Type 1 to Improve Quality of Life Standards, a Target Identification Collaboration
Brief Summary: Myotonic dystrophy type1 (DM1) is a rare, inherited, chronic progressive disease as well as an autosomal dominant multisystemic disorder. It is the most common adult form of muscular dystrophy, with a prevalence of approximately 10 per 100,000 people affected. With 733 million people in Europe, we estimate that 75,000 people are DM1 patients in Europe.

The aim of OPTIMISTIC is to improve clinical practice in the management of patients with this rare disease for which no dedicated treatment is currently available. OPTIMISTIC is a multi-centre, randomised controlled trial designed to compare a two component tailored behavioural change intervention to increase physical activity against standard patient management regimes, with particular attention given to the definition of appropriate outcome measures and new clinical guidelines for DM1 management. The two components of the intervention are 1) cognitive behavioural therapy (CBT) and 2) graded physical activity and we will evaluate the intervention's effectiveness and safety against standard patient management.

Participants will be recruited from myotonic dystrophy clinics and neuromuscular centres in France, Germany, the Netherlands and the UK. A total of 286 male and female patients aged 18 years and older with genetically proven classical or adult DM1 suffering from severe fatigue (only DM1 patients with a CIS subscale fatigue score \> 35 are likely to benefit from the intervention), able to walk independently and able to complete the trial interventions will be included.

A key objective of OPTIMISTIC is to provide outcome measures that are relevant for the patients and have a rate of change that is appropriate for a clinical trial timeframe. In addition, OPTIMISTIC will identify genetic factors that predict outcome and potential biomarkers as surrogate outcome measures that best explain the observed clinical variation.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Pulmonary Rehabilitation | Intervention Type: OTHER; Name: Pulmonary Rehabilitation; Assigned to Arm(s): Intervention
B: Arm Label: Behavioural change intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioural change intervention | Arm Label: Standard Patient Management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioural change intervention; Assigned to Arm(s): Behavioural change intervention
C: Arm Label: IVR Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: IVR Intervention Group | Arm Label: IVR Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: IVR Intervention Group; Assigned to Arm(s): IVR Intervention Group
D: Arm Label: Energetic; Type: EXPERIMENTAL; Interventions: Behavioral: Energetic | Arm Label: Control group; Type: OTHER; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: Energetic; Assigned to Arm(s): Energetic | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group

Answer: B